CSIMarket Company Name, Ticker, Suppliers, else..


Krystal Biotech Inc   (KRYS)
Other Ticker:  
 

Krystal Biotech Inc

KRYS's Fundamental analysis



Looking into Krystal Biotech Inc growth rates, revenue grew in II. Quarter 2024 from the same quarter a year ago. Ranking at No. 77

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 12.58 %

Krystal Biotech Inc realized net income compared to net loss a year ago in II. Quarter 2024

• More on KRYS's Growth


Krystal Biotech Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Krystal Biotech Inc PEG ratio is at -0.3 Company is currently trading with Price to Cash flow multiple of 76.13 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
49.7
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 32.02.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.92.


• More on KRYS's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,696,255
 Net Income/Employee (TTM) $ 1,081,010
 Receivable Turnover (TTM) 3.31
 Tangible Book Value (Per Share $) 28.31

Krystal Biotech Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Krystal Biotech Inc PEG ratio is at -0.3 Company is currently trading with Price to Cash flow multiple of 76.13 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
49.7
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 32.02.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.92.

Krystal Biotech Inc Price to Book Ratio is at 6.34 lower than Industry Avg. of 1052.41. and higher than S&P 500 Avg. of 0

• More on KRYS's Valuation

•  Market Capitalization (Millions $) 5,322
•  Shares Outstanding (Millions) 30
•  Employees 98
•  Revenues (TTM) (Millions $) 166
•  Net Income (TTM) (Millions $) 106
•  Cash Flow (TTM) (Millions $) 70
•  Capital Exp. (TTM) (Millions $) -6
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 1,696,255
•  Net Income/Employee(TTM) $ 1,081,010
•  Receivable Turnover Ratio (TTM) 3.31
•  Tangible Book Value (Per Share $) 28.31

•  Market Capitalization (Millions $) 5,322
•  Shares Outstanding (Millions) 30
•  Employees 98
•  Revenues (TTM) (Millions $) 166
•  Net Income (TTM) (Millions $) 106
•  Cash Flow (TTM) (Millions $) 70
•  Capital Exp. (TTM) (Millions $) -6


    KRYS's Profitability Comparisons
Krystal Biotech Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in II. Quarter 2024 to 12.19 %.

Krystal Biotech Inc net profit margin of 22.15 % is currently ranking no. 11 in Biotechnology & Pharmaceuticals industry, ranking no. 46 in Healthcare sector and number 543 in S&P 500.


Profitability by Segment
Total 22.15 %



  Ratio
•   Capital Ratio (MRQ) 9.5
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.09
•  Asset Turnover Ratio (TTM) 0.2
•  Inventory Turnover Ratio (TTM) -



Krystal Biotech Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in II. Quarter 2024 to 12.19 %.

Krystal Biotech Inc net profit margin of 22.15 % is currently ranking no. 11 in Biotechnology & Pharmaceuticals industry, ranking no. 46 in Healthcare sector and number 543 in S&P 500.

• More on KRYS's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com